When was Biogen founded?

Biogen was founded in 1978 and raised its 1st funding round 5 years after it was founded.

Where is Biogen located?

Biogen is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

How many employees does Biogen have?

As of Sep 30, 2026, the latest employee count at Biogen is 7853.

Is Biogen a funded company?

Biogen is a funded company, having raised a total of $80M across 3 funding rounds to date. The company's 1st funding round was a $***** PE round, raised on Feb 19, 1983.

When was the latest funding round of Biogen?

Biogen's latest funding was a $***** Post IPO round on Feb 13, 2024, with participation from 1 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $4.57B in funding in 2026 to date.

What is the annual revenue of Biogen?

Annual revenue of Biogen is more than $1B as on Dec 31, 2025

Where does Biogen rank among its competitors?

Biogen ranks 3rd amongst 3333 active competitors, of which 1097 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Biogen?

Biogen's top competitors include BeiGene, Jazz Pharmaceuticals and PTC Therapeutics. Among them, Immuneel secured the most recent funding round in June, 2026.

Biogen - 2026 Company Profile, Team, Funding, Competitors & Financials

Biogen is a public company based in Cambridge (United States), founded in 1978 by Phillip Allen Sharp, Heinz, Walter Gilbert, Kenneth Murray and Charles Weissmann. It operates as a Developer of therapies for neurodegenerative and immunology disorders. Biogen has raised $80M in funding. The company has 3333 active competitors, including 1097 funded and 813 that have exited. Its top competitors include companies like BeiGene, Jazz Pharmaceuticals and PTC Therapeutics.

Company Details

Developer of therapies for neurodegenerative and immunology disorders. The company has developed a pipeline of drugs for Alzheimer's disease Amyotrophic lateral sclerosis (ALS), Angelman syndrome, Brain contusion, Multiple sclerosis (MS), Multiple system atrophy (MSA), Ophthalmology, Pain, and more.

Website: www.biogen.com/
Social
Email ID: *****@biogen.com
Phone Number: +1 **********
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

1978

Location

Cambridge, United States

Stage

Public

Total Funding

$80M in 3 rounds

Latest Funding Round

Post IPO, Feb 13, 2024, $*****

Investors

Berkshire Hathaway & 12 more

Ranked

3^rd among 3333 active competitors

Annual Revenue

$1B+ as on Dec 31, 2025

Employee Count

7,853 as on Sep 30, 2026

Investment & Acquisitions

Altay Therapeutics & 42 more

Similar Companies

BeiGene & 1156 more

Exit Details

Public

View Biogen's full profile

Biogen is associated with 7 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Biogen Ma Inc. CIN: 20151245297 , United States, Active	Apr 08, 2015	-	-	-
BIOGEN PHARMA D.O.O. CIN: 76730068664 , Croatia, Active	Feb 17, 2020	€0 - €1M (As on Dec 31, 2024)	-
Biogen Estonia OÜ CIN: 14996084 , Estonia, Active	Jun 24, 2020	-	1 (As on Sep 30, 2024)
Biogen Inc. CIN: 875045 , United States, Active	Sep 22, 2014	$1B+ (As on Dec 31, 2025)	-	-
BIOGEN CAPABILITY CENTER INDIA PRIVATE LIMITED CIN: U62013KA2023FTC173057 , India, Active	Apr 30, 2023	₹50 - ₹100 Cr (As on Mar 31, 2025)	-
BIOGEN IDEC BIOTECH INDIA PRIVATE LIMITED CIN: U24232DL2007PTC305611 , India, Active	Mar 01, 2007	0 - ₹10 Cr (As on Mar 31, 2025)	-
Biogen Idec Inc. CIN: 330112644 , United States, Active	Dec 31, 1999	$1B+ (As on Dec 31, 2014)	4289 (As on Dec 31, 2024)	-

Biogen got listed on Sep 16, 1991.

Click here to take a look at Biogen's IPO in detail

Biogen has raised a total funding of $80M over 3 rounds. Its first funding round was on Feb 19, 1983. Its latest funding round was a Post IPO round on Feb 13, 2024 for $*****. 1 investor participated in its latest round. Biogen has 13 institutional investors.

Here is the list of recent funding rounds of Biogen:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 13, 2024	8343516	Post IPO	5164167	9964787	5887959	6776071
Jul 27, 2010	8030237	Grant (prize money)	6539635	7305140	1791041	HHS
Feb 19, 1983	6496286	PE	2218736	7610242	1227651	1332004

Access funding benchmarks and valuations. Sign up today!

View details of Biogen's funding rounds and investors

The founders of Biogen are Phillip Allen Sharp, Heinz, Walter Gilbert, Kenneth Murray and Charles Weissmann.

Here are the details of Biogen's key team members:

Phillip Allen Sharp: Co-Founder of Biogen and founder of 1 other company.
Contact Info: 1 email address
Heinz: Co-Founder of Biogen.
Walter Gilbert: Co-Founder of Biogen.
Kenneth Murray: Former Co-Founder of Biogen.
Charles Weissmann: Co-Founder of Biogen.
Contact Info: 1 email address

View details of Biogen's Founder profiles and Board Members

Biogen's employee count trend

Biogen has 7,853 employees as of Sep 26. Here is Biogen's employee count trend over the years:

Uncover Biogen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Biogen include BeiGene, Jazz Pharmaceuticals and PTC Therapeutics. Here is the list of Top 10 competitors of Biogen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
2nd	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
3rd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
4th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 29 others	77/100
5th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	76/100
6th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Biogen's competitors? Click here to see the top ones

Biogen has made 30 investments in companies including Altay Therapeutics and Dayra Therapeutics. Biogen has also acquired 13 companies including RayThera and Apellis Pharmaceuticals.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Sep 17, 2026	Investments	Altay Therapeutics	2019	San Francisco (United States)
Jun 17, 2026	Acquisition	RayThera	2023	San Diego (United States)
Mar 31, 2026	Acquisition	Apellis Pharmaceuticals	2008	Crestwood (United States)